Strengthening the reporting of genetic risk prediction studies: The GRIPS statement

Genome Medicine

Volumn 3, Issue 3, 2011, Pages

  Janssens, A Cecile J W ^a   Ioannidis, John P A ^b,c,d,e,f   van Duijn, Cornelia M ^a   Little, Julian ^g   Khoury, Muin J ^h  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b UNIVERSITY OF IOANNINA   (Greece)

^c INSTITUTE OF COMPUTER SCIENCE   (Greece)

^d TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e TUFTS MEDICAL CENTER   (United States)

^f STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^g UNIVERSITY OF OTTAWA   (Canada)

^h NATIONAL CENTER ON BIRTH DEFECTS AND DEVELOPMENTAL DISABILITIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GENETIC RISK; GENETIC VARIABILITY; GENOTYPE; HUMAN; LETTER; METHODOLOGY; PRACTICE GUIDELINE; PREDICTION; PRIORITY JOURNAL;

EID: 79952751033     PISSN: None     EISSN: 1756994X     Source Type: Journal    
DOI: 10.1186/gm230     Document Type: Letter

References (28)

1. Khoury MJ, Gwinn M, Yoon PW, Dowling N, Moore CA, Bradley L. The continuum of translation research in genomic medicine: how can we accelerate the appropriate integration of human genome discoveries into health care and disease prevention?. Genet Med 2007, 9:665-674. 10.1097/GIM.0b013e31815699d0, 18073579.
2. Hlatky MA, Greenland P, Arnett DK, Ballantyne CM, Criqui MH, Elkind MS, Go AS, Harrell FE, Hong Y, Howard BV, Howard VJ, Hsue PY, Kramer CM, McConnell JP, Normand SL, O'Donnell CJ, Smith SC, Wilson PW, . American Heart Association Expert Panel on Subclinical Atherosclerotic Diseases and Emerging Risk Factors and the Stroke Council Criteria for evaluation of novel markers of cardiovascular risk: a scientific statement from the American Heart Association. Circulation 2009, 119:2408-2416. 10.1161/CIRCULATIONAHA.109.192278, 2956982, 19364974, American Heart Association Expert Panel on Subclinical Atherosclerotic Diseases and Emerging Risk Factors and the Stroke Council.
3. Kyzas PA, Denaxa-Kyza D, Ioannidis JP. Quality of reporting of cancer prognostic marker studies: association with reported prognostic effect. J Natl Cancer Inst 2007, 99:236-243. 10.1093/jnci/djk032, 17284718.
4. Kyzas PA, Loizou KT, Ioannidis JP. Selective reporting biases in cancer prognostic factor studies. J Natl Cancer Inst 2005, 97:1043-1055. 10.1093/jnci/dji184, 16030302.
5. McShane LM, Altman DG, Sauerbrei W, Taube SE, Gion M, Clark GM, . Statistics Subcommittee of NCI-EORTC Working Group on Cancer Diagnostics REporting recommendations for tumor MARKer prognostic studies (REMARK). Nat Clin Pract Urol 2005, 2:416-422. 10.1038/ncponc0252, 16482653, Statistics Subcommittee of NCI-EORTC Working Group on Cancer Diagnostics.
6. Kyzas PA, Denaxa-Kyza D, Ioannidis JP. Almost all articles on cancer prognostic markers report statistically significant results. Eur J Cancer 2007, 43:2559-2579.
7. Tzoulaki I, Liberopoulos G, Ioannidis JP. Assessment of claims of improved prediction beyond the Framingham risk score. JAMA 2009, 302:2345-2352. 10.1001/jama.2009.1757, 19952321.
8. von Elm E, Egger M. The scandal of poor epidemiological research. BMJ 2004, 329:868-869. 10.1136/bmj.329.7471.868, 523097, 15485939.
9. Simera I, Moher D, Hoey J, Schulz KF, Altman DG. A catalogue of reporting guidelines for health research. Eur J Clin Invest 2010, 40:35-53. 10.1111/j.1365-2362.2009.02234.x, 20055895.
10. von Elm E, Altman DG, Egger M, Pocock SJ, Gotzsche PC, Vandenbroucke JP, . Iniciativa STROBE The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. PLoS Med 2007, 4:e296. 10.1371/journal.pmed.0040296, 2020495, 17941714, Iniciativa STROBE.
11. Little J, Higgins JP, Ioannidis JP, Moher D, Gagnon F, von Elm E, Khoury MJ, Cohen B, Davey-Smith G, Grimshaw J, Scheet P, Gwinn M, Williamson RE, Zou GY, Hutchings K, Johnson CY, Tait V, Wiens M, Golding J, van Duijn C, McLaughlin J, Paterson A, Wells G, Fortier I, Freedman M, Zecevic M, King R, Infante-Rivard C, Stewart A, Birkett N. STrengthening the REporting of Genetic Association Studies (STREGA): an extension of the STROBE statement. PLoS Med 2009, 6:e22. 10.1371/journal.pmed.1000022, 2634792, 19192942.
12. Bossuyt PM, Reitsma JB, Bruns DE, Gatsonis CA, Glasziou PP, Irwig LM, Lijmer JG, Moher D, Rennie D, de Vet HC, . STARD Group Towards complete and accurate reporting of studies of diagnostic accuracy: the STARD initiative. BMJ 2003, 326:41-44. 10.1136/bmj.326.7379.41, 1124931, 12511463, STARD Group.
13. McShane LM, Altman DG, Sauerbrei W, Taube SE, Gion M, Clark GM, . Statistics Subcommittee of the NCI-EORTC Working Group on Cancer Diagnostics Reporting recommendations for tumor marker prognostic studies. J Clin Oncol 2005, 23:9067-9072. 10.1200/JCO.2004.01.0454, 16172462, Statistics Subcommittee of the NCI-EORTC Working Group on Cancer Diagnostics.
14. Janssens AC, Van Duijn CM. Genome-based prediction of common diseases: methodological considerations for future research. Genome Med 2009, 1:20. 10.1186/gm20, 2664953, 19341491.
15. Khoury MJ, Gwinn M, Ioannidis JP. The emergence of translational epidemiology: from scientific discovery to population health impact. Am J Epidemiol 2010, 172:517-524. 10.1093/aje/kwq211, 2927741, 20688899.
16. Moons KG, Altman DG, Vergouwe Y, Royston P. Prognosis and prognostic research: application and impact of prognostic models in clinical practice. BMJ 2009, 338:b606. 10.1136/bmj.b606, 19502216.
17. Khoury MJ, Dorman JS. The Human Genome Epidemiology Network. Am J Epidemiol 1998, 148:1-3.
18. Equator Network. , http://www.equator-network.org
19. Freedman AN, Seminara D, Gail MH, Hartge P, Colditz GA, Ballard-Barbash R, Pfeiffer RM. Cancer risk prediction models: a workshop on development, evaluation, and application. J Natl Cancer Inst 2005, 97:715-723. 10.1093/jnci/dji128, 15900041.
20. PLoS Medicine. , http://www.plosmedicine.org
21. Altman DG, Schulz KF, Moher D, Egger M, Davidoff F, Elbourne D, Gøtzsche PC, Lang T, . CONSORT GROUP (Consolidated Standards of Reporting Trials) The revised CONSORT statement for reporting randomized trials: explanation and elaboration. Ann Intern Med 2001, 134:663-694. CONSORT GROUP (Consolidated Standards of Reporting Trials).
22. Bossuyt PM, Reitsma JB, Bruns DE, Gatsonis CA, Glasziou PP, Irwig LM, Moher D, Rennie D, de Vet HC, Lijmer JG, . Standards for Reporting of Diagnostic Accuracy The STARD statement for reporting studies of diagnostic accuracy: explanation and elaboration. Ann Intern Med 2003, 138:W1-12. Standards for Reporting of Diagnostic Accuracy.
23. Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gotzsche PC, Ioannidis JP, Clarke M, Devereaux PJ, Kleijnen J, Moher D. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. PLoS Med 2009, 6:e1000100. 10.1371/journal.pmed.1000100, 2707010, 19621070.
24. Vandenbroucke JP, von Elm E, Altman DG, Gotzsche PC, Mulrow CD, Pocock SJ, Poole C, Schlesselman JJ, Egger M, . STROBE Initiative Strengthening the Reporting of Observational Studies in Epidemiology (STROBE): explanation and elaboration. PLoS Med 2007, 4:e297. 10.1371/journal.pmed.0040297, 2020496, 17941715, STROBE Initiative.
25. Vandenbroucke JP. STREGA, STROBE, STARD, SQUIRE, MOOSE, PRISMA, GNOSIS, TREND, ORION, COREQ, QUOROM, REMARK... and CONSORT: for whom does the guideline toll?. J Clin Epidemiol 2009, 62:594-596. 10.1016/j.jclinepi.2008.12.003, 19181482.
26. Cook NR. Use and misuse of the receiver operating characteristic curve in risk prediction. Circulation 2007, 115:928-935. 10.1161/CIRCULATIONAHA.106.672402, 17309939.
27. Pencina MJ, D'Agostino RB, D'Agostino RB, Vasan RS. Evaluating the added predictive ability of a new marker: from area under the ROC curve to reclassification and beyond. Stat Med 2008, 27:157-172. 10.1002/sim.2929, 17569110.
28. Janssens AC, Khoury MJ. Assessment of improved prediction beyond traditional risk factors: when does a difference make a difference?. Circ Cardiovasc Genet 2010, 3:3-5. 10.1161/CIRCGENETICS.110.938092, 20160189.